For Biohaven Ltd. (BHVN), a global clinical-stage biopharmaceutical company focused on developing life-changing therapies for rare and common diseases, the second half of 2026 could be a defining chapter, with pivotal data readouts poised to shape the future of its diverse pipeline.
At the core of this innovation are its novel platforms, MoDE and TRAP, designed to target the root causes of autoimmune diseases. MoDE targets a class of proteins implicated in disease pathogenesis, while TRAP selectively removes disease-causing proteins while leaving the rest of the immune system intact.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com